Cargando…
Targeting IL-6 Is a Potential Treatment for Primary Cystic Craniopharyngioma
Adamantinomatous craniopharyngioma (ACP) makes up between 6 and 8% of pediatric brain tumors and is the most common pediatric tumor arising in the sellar/suprasellar region of the brain. The 10-year survival for patients diagnosed with craniopharyngioma ranges between 64 and 92%, but complicating fa...
Autores principales: | Grob, Sydney, Mirsky, David M., Donson, Andrew M., Dahl, Nathan, Foreman, Nicholas K., Hoffman, Lindsey M., Hankinson, Todd C., Mulcahy Levy, Jean M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6712354/ https://www.ncbi.nlm.nih.gov/pubmed/31497533 http://dx.doi.org/10.3389/fonc.2019.00791 |
Ejemplares similares
-
RARE-32. Phase 0 and feasibility single-institution clinical trial of intravenous tocilizumab for adamantinomatous craniopharyngioma
por: Dorris, Kathleen, et al.
Publicado: (2022) -
Adamantinomatous craniopharyngioma associated with a compromised blood–brain barrier: patient series
por: Prince, Eric W., et al.
Publicado: (2021) -
RONC-05. Peri-transplant Radiation Therapy for Young Children Treated with High-Dose Chemotherapy for Primary Brain Tumors
por: Milgrom, Sarah, et al.
Publicado: (2022) -
MODL-24. AN ORGANOTYPIC CHUNK CULTURE TECHNIQUE TO STUDY DISEASE MECHANISM AND DEVELOP TARGETED THERAPEUTICS FOR PEDIATRIC ADAMANTINOMATOUS CRANIOPHARYNGIOMA
por: Vijmasi, Trinka, et al.
Publicado: (2020) -
RARE-10. ADAMANTINOMATOUS CRANIOPHARYNGIOMA RESIDES OUTSIDE THE BLOOD BRAIN BARRIER
por: Prince, Eric, et al.
Publicado: (2020)